Eiger BioPharmaceuticals to Participate in Upcoming September 2021 Investor Conferences
- Citi's 16th Annual
BioPharma Virtual Conference
- "Finding a Needle in a Haystack – Drug Development Strategies for Rare Disease" panel discussion
Thursday, September 9at 4:10 PM ET
- Baird's 2021 Global Healthcare Conference
- Corporate update
Wednesday, September 15at 2:00 PM ET
A live webcast of the Citi panel discussion will be available on the
Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases.
Zokinvy® for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient progeroid laminopathies is the Company's first FDA approved product. A Marketing Authorization Application (MAA) is under review by the European Medicines Agency (EMA).
For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Investors and Media:
Email: [email protected]
Phone: 1-650-272-6138 ext. 1007
View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-participate-in-upcoming-september-2021-investor-conferences-301367766.html